Plasma-based APOE genotyping to add genetic risk data to a diverse, deeply characterized Alzheimer’s biomarker cohort
PRINCETON, N.J., and NEW HAVEN, Conn., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc. (NASDAQ: NIKI) (“Niki” or the “Company”), a clinical-stage life sciences company focused on unmet medical needs and genomic and biomarker testing solutions, today announced that its wholly owned subsidiary, DiamiR Biosciences Corp. (“DiamiR”), will perform apolipoprotein E (APOE) genotyping on plasma samples from the Global Alzheimer’s Platform Foundation® (“GAP”) Bio-Hermes-002 study cohort.
The APOE ε4 allele is the strongest known genetic risk factor for late-onset Alzheimer’s disease, and APOE genotype informs clinical trial design and enrollment as well as risk assessment for amyloid-related imaging abnormalities (ARIA) with anti-amyloid therapies. Genotyping directly from banked plasma adds genetic information to existing samples without additional blood draws.
Bio-Hermes-002 is a GAP-sponsored observational study comparing blood-based and digital biomarkers with amyloid PET imaging and cognitive assessments in cognitively normal participants, those with mild cognitive impairment, or those with mild Alzheimer’s disease, with an emphasis on recruiting from underrepresented communities. DiamiR will use its New York State-approved, plasma-based APOE genotyping assay, and the resulting data will be integrated with the Bio-Hermes dataset and may be available to the research community consistent with GAP’s data-sharing practice.
“We are proud to contribute DiamiR’s plasma-based APOE genotyping to the Bio-Hermes cohort,” said Alidad Mireskandari, Ph.D., MBA, President and Chief Operating Officer of Niki BioSolutions. “Determining APOE status from plasma unlocks the value of samples already collected, helping researchers better interpret blood-based biomarkers and design more efficient trials. This collaboration also expands our visibility with the biopharma and diagnostics companies that rely on Bio-Hermes data.”
“Bio-Hermes was designed to give the field data that will enhance the design and execution of Alzheimer's clinical trials,” said John Dwyer, President & CEO of the Global Alzheimer’s Platform Foundation. “We are pleased to collaborate with DiamiR. Adding APOE genotype makes Bio-Hermes an even more valuable resource.”
About Niki BioSolutions
Niki BioSolutions is a clinical-stage life sciences company focused on unmet medical needs and high-quality genomic and biomarker testing solutions to healthcare providers, research institutions, and life sciences organizations through its CLIA-certified, CAP-accredited laboratory. The company combines proprietary technologies with a commitment to scientific rigor to support precision medicine across a range of therapeutic areas, including neurodegeneration and other brain health conditions. Niki BioSolutions collaborates with leading academic centers, disease foundations, and biopharma companies.
About the Global Alzheimer’s Platform Foundation (GAP)
The Global Alzheimer's Platform Foundation® (GAP) is dedicated to accelerating the delivery of treatments, therapies, and cures for people living with neurodegenerative diseases, like Alzheimer's, Parkinson's and Multiple Sclerosis. GAP works to lower costs and improve the efficacy of clinical trials and is committed to ensuring that no one is left behind. As part of its mission, GAP supports more than 75 clinical research sites worldwide through study start-up and recruitment activities, promotes diversity in research studies, and champions the citizen scientists who make research possible.
For more information, visit www.globalalzplatform.org.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often use words such as “believe,” “may,” “will,” “estimate,” “target,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “propose,” “plan,” “project,” “forecast,” “predict,” “potential,” “seek,” “future,” “outlook,” and similar variations and expressions. Forward-looking statements are those that do not relate strictly to historical or current facts. Examples of forward-looking statements may include, among others, Niki BioSolutions’ ability to successfully operate its business and provide value to stockholders; Niki BioSolutions’ future financial, business and operating performance and goals; annualized recurring revenue and customer retention; ongoing or future ability to maintain or improve its financial position, cash flows, and liquidity and its expected financial needs; potential financing and ability to obtain financing; acquisition strategy and proposed acquisitions and, if completed, their potential success and financial contributions; strategy and strategic goals, including being able to capitalize on opportunities; expectations relating to Niki BioSolutions and its industry, outlook and market trends; total addressable market and serviceable addressable market and related projections; plans, strategies and expectations for increasing revenue and executing growth initiatives. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity and development of the industries in which Niki BioSolutions operates may differ materially from those made in or suggested by the forward-looking statements. Therefore, investors should not rely on any of these forward-looking statements. Factors that may cause actual results to differ materially include changes in the markets in which Niki BioSolutions operates, the financial markets, economic, business and regulatory factors, and other factors, such as Niki BioSolutions’ ability to execute on its strategies. More detailed information about risk factors can be found in the registration statement on Form S-4 filed with the Securities and Exchange Commission (the “SEC”) on October 6, 2025 (File No. 333-290742), and in other reports filed under the company’s prior name, Aptorum Group Limited, and that Niki BioSolutions will file with the SEC. Niki BioSolutions does not undertake any duty to update forward-looking statements after the date of this press release.
Investor Contact:
Lytham Partners, LLC
Ben Shamsian
646-829-9701
shamsian@lythampartners.com
GAP Media Contact:
Julie Sipchen
773-354-3360
media@globalalzplatform.org
###
